New hope for drug-resistant lung cancer: combo therapy tested in early trial

This early-phase trial tested two experimental drug combinations in 37 people with advanced EGFR-mutant lung cancer that no longer responded to the targeted therapy osimertinib. The goal was to find safe, tolerable doses of alisertib or sapanisertib when given together with osimertinib, and to see if these combinations could help control the cancer. The study is completed, and results will guide future research.